NASD · Healthcare · Biotechnology · USA
Zymeworks BC Inc is a small cap company (market value between $300 million and $2 billion) in the Biotechnology industry.
Zymeworks is a biotechnology company developing multifunctional biotherapeutics for cancer, inflammation, and autoimmune disease. The company manages a portfolio of licensed healthcare assets through partnerships with organizations like Jazz Pharmaceuticals and Johnson & Johnson, generating milestone payments and royalties. Its pipeline includes proprietary multispecific antibody therapeutics and antibody-drug conjugates, with wholly-owned candidates targeting solid tumors and inflammatory conditions.
From its FY2025 annual report (Form 10-K)
Intrinsic value, DCF valuation, financial health and value investing analysis for the Zymeworks BC Inc stock.
Overvalued: intrinsic value $3.64 per share, market price $25.84, margin of safety -609.0% (as of 2026-11-17).
Discounting its cash flows at 10.1% (average of 2 methods) values the shares at $3.64; the price of $25.84 is 609% above that value, and 72% of that value comes from beyond year five.
17 more funds hold it; the full list is part of the paid plan.
97 more in this industry show a wider margin of safety.
ZYME is overvalued (as of the 2026-11-17 close). Discounting its cash flows at 10.1% (average of 2 methods) values the shares at $3.64; the price of $25.84 is 609% above that value, and 72% of that value comes from beyond year five.
$3.64 per share (as of the 2026-11-17 close), against a market price of $25.84. That is a margin of safety of -609.0%. The value is the average of the 2 valuation methods that apply to this company, recomputed every night after the US close.